SOPHARMA AD: Notification

opublikowano: 2017-01-06 13:06

Spis treści:

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załącznikĂłw:
Notification_06.01.17.doc (REPORT)

	POLISH FINANCIAL SUPERVISION AUTHORITY
				UNI - EN REPORT No		1	/	2017
	Date of issue:		2017-01-06
	Short name of the issuer
	SOPHARMA AD
	Subject
	Notification
	Official market - legal basis
	art. 17. 1 MAR.
	Unofficial market - legal basis
	Contents of the report:
	2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab – Achieve – is undertaking a merger with another strong player in the development and registration of innovative medicines – Oncogenex, a publicly traded company on NASDAQ (http://in.reuters.com/article/idINFWN1EV0QP). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017. Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.
	Annexes
	File				Description
	Notification_06.01.17.docNotification_06.01.17.doc				Notification

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification
of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

16

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

nd

(NIP)

(REGON)

	SIGNATURE OF PERSONS REPRESENTING THE COMPANY
	Date	Name	Position / Function	Signature
	2017-01-06	Ognain Donev	Executive director